Frederik Peeters

PhD researcher on hepatocellular carcinoma @UZLeuven & @vib_ccb 🇧🇪
MD - Resident internal medicine.

[Jeroen Dekervel @JDekervel]

🎙️ New #ESMO Podcast – Controversies in Upper GI Cancers

📌 Radiotherapy in borderline resectable #PDAC:
Evidence vs practice �� when does it make sense?

@NiuSanford & @BasGrootKoerkam join me to discuss a case & key trials.

🎧 Listen: https://t.co/mgtMiKFkUI

#PancreaticCancer

[Jeroen Dekervel @JDekervel]

🎧 New @myESMO upper GI podcast!

We unpack key #ASCO25 updates in #PancreaticCancer & #BiliaryCancer:

✔️ CASSANDRA
✔️ PANOVA-3
✔️ Elraglusib
✔️ GAIN & POLCA-GB

w/ @ArndtVogel & Florian Castet

🎙 Listen: https://t.co/piDDivgNtQ

#GIonc

[andrea casadei gardini @casadei_gardini]

Excited to share our new study published in JNCI! 🧬
In >500 real-world BTC pts treated with cisplatin, gemcitabine & durvalumab, we found:
✔️ SMAD4 mut = better outcomes
❌ TP53 & TERT mut = worse survival
🔬 A new clinico-molecular score for patients

https://t.co/RS2BSYVEl7

[Tamsin Cargill @TamCarg]

It was an honour to host the @EASLedu Basic Science School at the TGLU Oxford @TGU_Oxford @NDMOxford with a brilliant keynote from @druppygill and lots of hands on learning in the lab. Great to connect with delegates from across the world @DavidTrampert @DraMartaAlonsoP

[andrea casadei gardini @casadei_gardini]

🔬 our last study on #BTC patients

Our findings reveal key clinical and molecular factors linked to maintenance #immunotherapy with #durvalumab in advanced BTC. These insights could guide better patient selection and personalized treatments.
https://t.co/PLNiGqNl0a

[Arndt Vogel @ArndtVogel]

Five-year OS update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC
@JHepatology
https://t.co/wrmzv3agRm
👉OS rate at 5 yrs: 19.6% vs 9.4%
🧐Interesting OS data for pts w/ disease control & any degree of tumour shrinkage
@myESMO @EASLedu @ILCAnews

[Jeroen Dekervel @JDekervel]

Cell by cell, we shall unravel the contribution of components in patients with #HCC treated with atezo/bev… https://t.co/e1sP3pTKJR

[HEPATOLOGY Journal @HEP_Journal]

Original Article
Outcome and management of patients with hepatocellular carcinoma who achieved complete response to immunotherapy-based systemic therapy

Scheiner et al.
#LiverX
https://t.co/uMMVd2fC0O

[Jeroen Dekervel @JDekervel]

Clinical and molecular variables associated with early progression to checkpoint inhibitors in MSI-high metastatic colorectal cancer: a retrospective cohort study.

https://t.co/krvolqOPBc

[Jeroen Dekervel @JDekervel]

A deep dive by @FlorianLordick into the #ESOPEC data presented at #ASCO24 - watch the video! 🎥

👇

[UZ Leuven @UZLeuven]

Baanbrekende studie TRANSMET toont het aan: patiënten met uitgezaaide dikkedarmkanker naar de lever kunnen geholpen worden met een #levertransplantatie. "Voor jongere kankerpatiënten met een levertumor uit de darm betekent dit de kans op een nieuw leven."
https://t.co/DSgTQ0HQtS

[Sarah Cappuyns @CappuynsSarah]

Check out poster 507-TOP @EASL2024.

👉Immune- versus angiogenesis-driven response to #atezobev in #aHCC
⛔️ Resistance related to TREM2+ macros and stromal activation
❗️associated with survival

Also, best Poster Award, third year in a row, still can't quite believe it...

[Arndt Vogel @ArndtVogel]

NIVO + IPI vs LEN (90%) or SORA as 1st line treatment for HCC #ASCO24
🤩Exciting times: More & more options in 1st line HCC
💪Clear improvement in OS with ICI based therapy & sequential therapy
🎯Now, we need biomarkers to guide treatment decisions
@myESMO @ILCA @EASL #livertwitter

[CCB_VIB_KUL @vib_ccb]

Last weekend, a CCB delegation cycled the #1000km of @komop_tgkanker 🚴🚴
Together with 1250 other teams, they managed to collect almost 7M EUR to support cancer research!

Amazing effort, amazing team 🤩
Thank you Bram, Shauni, Isabelle, Lars, Alexandra, Frederik en Amelie!

[Jeroen Dekervel @JDekervel]

Check out our #openaccess review on single-cell omics for liver cancer research including nice figures (by @PeetersFre) and an overview table of all previous efforts! @JHEP_Reports

[Jeroen Dekervel @JDekervel]

Special issue of #COPHAR on GI cancer is finally complete

Overview 👉 https://t.co/xM5MPSbPml

🙏 @AngelicaSSophie for editing

🙏 all contributors - @jcloydmd, @michele_ghidini, @IreneChong6, @RonaYaeger, @FedericaPapacc1, @PeetersFre and many others!!

[Jeroen Dekervel @JDekervel]

Tissue is the issue, also in #HCC ❗️

[UZ Leuven @UZLeuven]

Leuvense onderzoekers keken met single cell technologie tot op het diepste niveau van de cellen in de tumor en vonden een #biomerker die kan voorspellen of een patiënt met #leverkanker zal reageren op #immuuntherapie of niet. 🔬

Meer weten? 👉https://t.co/zxhg1ejWJd

[Jeroen Dekervel @JDekervel]

📢📢 PAPER OUT !!
🤔What biology underlies response to #atezobev in #HCC ?

🔬scRNA and scTCR sequencing of tumour and blood samples

🔜tweetorial of the amazing @CappuynsSarah

🙏Fruitful collaboration with @LambrechtsDlab

👀#OpenAccess Paper is here: https://t.co/zohwSm3jGJ

[EASLnews @EASLnews]

🌟 October is #LiverCancerAwarenessMonth, a time to shed light on the various types of liver cancers. 🌟
Liver cancers originate in different liver cells, and understanding them is crucial for early detection and treatment. Knowing these types and their unique characteristics is a step towards early diagnosis and better outcomes.

Share this information to raise awareness and save lives! 💚

https://t.co/L5YehZoiVm

@EASLEUAffairs @dice_europe @EuropeLiver @ILCAnews